Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

21.34
+0.11000.52%
Post-market: 21.340.00000.00%19:30 EDT
Volume:571.85K
Turnover:12.30M
Market Cap:1.36B
PE:-9.11
High:22.12
Open:21.45
Low:21.13
Close:21.23
52wk High:28.00
52wk Low:6.91
Shares:63.60M
Float Shares:47.12M
Volume Ratio:0.62
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.47
PE(LYR):-6.68

Loading ...

Company Profile

Company Name:
Jade Biosciences
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
55
Office Location:
Building 23,Suite 105,221 Crescent Street,Waltham,Massachusetts,United States
Zip Code:
02453
Fax:
- -
Introduction:
Jade Biosciences, Inc. was originally incorporated in Delaware as Aerovate Therapeutics, Inc. in July 2018. Following a merger and redomiciliation completed in April 2025, the company is now a Nevada corporation focused on developing novel biologic therapies for patients with autoimmune diseases. Its lead candidate, JADE101, targets APRIL for the treatment of IgA nephropathy, with additional programs targeting BAFF-R and other undisclosed pathways.

Directors

Name
Position
Tom Frohlich
Chief Executive Officer and Director
Chris Cain
Independent Director
Eric L. Dobmeier
Chair and Independent Director
Erin M. Lavelle
Independent Director
Lawrence Otto Klein
Independent Director
Tomas Kiselak
Independent Director

Shareholders

Name
Position
Tom Frohlich
Chief Executive Officer and Director
Bradford Dahms
Chief Financial Officer and Treasurer
Andrew James King
Chief Scientific Officer and Head of Research & Development
Elizabeth Balta
Corporate Secretary and General Counsel